A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
News|Articles|June 26, 2026
Previewing women's health regulatory updates and conferences in the 2nd half of 2026
Author(s)Contemporary OB/GYN Staff
Fact checked by: Joshua Fitch, Senior Editor
A look ahead to the second half of 2026 for ob-gyns, including Viatris's pending FDA decision on a low-dose estrogen contraceptive patch and previews of the IDSOG, AUGS PFD Week, and The Menopause Society annual meetings.
Advertisement
Advertisement
We're officially at the halfway point of the year, and the back half is shaping up to be just as active as the first for women's health. Below, the Contemporary OB/GYN team looks ahead to a pending FDA decision in the contraception space, along with the leading medical society meetings on the calendar for the remainder of 2026.
Related to this article
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
ACOG issued its most comprehensive menopause guidance, grading treatments for VMS, sleep, and mood symptoms.
Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.
Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Advertisement
Advertisement